Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. Calithera is headquartered in South San Francisco, California.
Company profile
Ticker
CALA
Exchange
Website
CEO
Susan Molineaux
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
CALA stock data
Latest filings (excl ownership)
CT ORDER
Confidential treatment order
15 Jun 23
DEFM14A
Proxy related to merger
5 Jun 23
PREM14A
Preliminary proxy related to merger
26 May 23
DEFA14A
Additional proxy soliciting materials
19 May 23
10-K
2022 FY
Annual report
30 Mar 23
EFFECT
Notice of effectiveness
20 Mar 23
15-12G
Securities registration termination
14 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 23
Transcripts
CALA
Earnings call transcript
2022 Q3
15 Nov 22
CALA
Earnings call transcript
2022 Q2
16 Aug 22
CALA
Earnings call transcript
2022 Q1
11 May 22
CALA
Earnings call transcript
2021 Q4
1 Apr 22
CALA
Earnings call transcript
2021 Q3
10 Nov 21
CALA
Earnings call transcript
2021 Q2
8 Aug 21
CALA
Earnings call transcript
2021 Q1
9 May 21
CALA
Earnings call transcript
2020 Q4
17 Mar 21
CALA
Earnings call transcript
2020 Q3
7 Nov 20
CALA
Earnings call transcript
2020 Q2
10 Aug 20
Latest ownership filings
SC 13D/A
TAKEDA PHARMACEUTICAL CO LTD
26 May 23
4
Change in insider ownership
26 May 23
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 23
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 23
SC 13G/A
PRIMECAP MANAGEMENT CO/CA/
9 Feb 23
SC 13G/A
PRIMECAP MANAGEMENT CO/CA/
9 Feb 23
SC 13G/A
INCYTE CORP
8 Feb 23
4
DEEPIKA PAKIANATHAN
31 Jan 23
4
Eric Sjogren
25 Jan 23
4
Emil Kuriakose
25 Jan 23
Financial summary
Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 25.70 mm | 25.70 mm | 25.70 mm | 25.70 mm | 25.70 mm | 25.70 mm |
Cash burn (monthly) | 2.87 mm | 2.84 mm | 2.45 mm | 3.51 mm | 2.87 mm | 3.63 mm |
Cash used (since last report) | 45.51 mm | 45.11 mm | 38.87 mm | 55.66 mm | 45.50 mm | 57.69 mm |
Cash remaining | -19.81 mm | -19.41 mm | -13.17 mm | -29.96 mm | -19.80 mm | -31.99 mm |
Runway (months of cash) | -6.9 | -6.8 | -5.4 | -8.5 | -6.9 | -8.8 |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 0 |
Closed positions | 20 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 33.78 mm |
Total shares | 15.51 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
TAK Takeda Pharmaceutical | 14.82 mm | $29.78 mm |
Biotechnology Value Fund L P | 488.37 k | $0.00 |
Primecap Management | 199.96 k | $82.00 k |
FinTrust Capital Advisors | 1.20 k | $3.92 mm |
INCY Incyte | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Apr 23 | Takeda Pharmaceutical | Series A Convertible Preferred Stock Common Stock | Other | Dispose J | Yes | No | 40.08 | 1,000,000 | 40.08 mm | 0 |
27 Jan 23 | Pakianathan Deepika | Common Stock | Sell | Dispose S | Yes | No | 0.3858 | 1,172 | 452.16 | 0 |
27 Jan 23 | Pakianathan Deepika | Common Stock | Sell | Dispose S | Yes | No | 0.3858 | 120,161 | 46.36 k | 0 |
23 Jan 23 | Emil Kuriakose | Common Stock | Payment of exercise | Dispose F | No | No | 0.4461 | 79 | 35.24 | 3,539 |
23 Jan 23 | Molineaux Susan | Common Stock | Payment of exercise | Dispose F | Yes | No | 0.4461 | 526 | 234.65 | 27,859 |
23 Jan 23 | Christopher Molineaux | Common Stock | Payment of exercise | Dispose F | Yes | No | 0.4461 | 217 | 96.80 | 27,859 |